Financial News
FDA pulls Covid antibody treatment because it's not effective against dominant omicron variants
December 01, 2022 at 16:32 PM EST
The FDA said bebtelovimab is no longer authorized for use because it is not expected to neutralize the omicron BQ.1 and BQ.1.1 subvariants.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
